Citation

Doernberg M, Krawczyk N, Agus D, Fingerhood M. Subst. Abuse 2019; ePub(ePub): 1-6.

Affiliation

Johns Hopkins School of Medicine , Baltimore , Maryland , USA.

Copyright

(Copyright © 2019, Informa - Taylor and Francis Group)

DOI

10.1080/08897077.2019.1572052

PMID

31008694

Abstract

Buprenorphine is considered one of the most effective treatments for opioid use disorder and significantly reduces risk of overdose death. However, concerns about its diversion and misuse have often taken center stage in public discourse and in the design of practices and policies regarding its use. This has been to the detriment of many vulnerable patient populations, especially those involved in the criminal justice system. Policies that restrict access to buprenorphine in criminal justice and other settings due to concerns of diversion do not accurately reflect the relative risks and safety profile associated with it, creating unnecessary barriers that drive an illicit market of this much-needed medication. Although proper regulation of all controlled medications should be a priority, in most instances the benefits of buprenorphine highly outweigh its risks. In the midst of a national crisis, efforts should be focused on expanding, and not restricting, access to this lifesaving treatment.

Language: en

Keywords

Addiction; buprenorphine; criminal justice; diversion; opioid; substance use